These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 22791814

  • 1. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
    Tseng HY, Chen LH, Ye Y, Tay KH, Jiang CC, Guo ST, Jin L, Hersey P, Zhang XD.
    Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
    [Abstract] [Full Text] [Related]

  • 2. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P.
    Cancer Res; 2007 Jun 15; 67(12):5880-8. PubMed ID: 17575157
    [Abstract] [Full Text] [Related]

  • 3. Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response.
    Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne RF, Zhang XD, Hersey P.
    Carcinogenesis; 2007 Nov 15; 28(11):2328-36. PubMed ID: 17652336
    [Abstract] [Full Text] [Related]

  • 4. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schön MP, Henkler F, Gollnick H, Walczak H, Leverkus M.
    Oncogene; 2008 May 15; 27(22):3211-20. PubMed ID: 18084329
    [Abstract] [Full Text] [Related]

  • 5. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 6. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J.
    Oncogene; 2007 May 17; 26(23):3364-77. PubMed ID: 17160022
    [Abstract] [Full Text] [Related]

  • 7. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, Park JW, Choi KS, Kwon TK.
    Free Radic Biol Med; 2008 Mar 15; 44(6):1055-68. PubMed ID: 18164688
    [Abstract] [Full Text] [Related]

  • 8. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 9. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T.
    Mol Cancer Res; 2008 Dec 15; 6(12):1852-60. PubMed ID: 19074830
    [Abstract] [Full Text] [Related]

  • 10. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):543-52. PubMed ID: 18793956
    [Abstract] [Full Text] [Related]

  • 11. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS.
    Cancer Res; 2008 Jan 01; 68(1):266-75. PubMed ID: 18172319
    [Abstract] [Full Text] [Related]

  • 13. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B.
    Mol Cancer Res; 2009 Nov 01; 7(11):1835-44. PubMed ID: 19843632
    [Abstract] [Full Text] [Related]

  • 14. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.
    Li J, Anderson MG, Tucker LA, Shen Y, Glaser KB, Shah OJ.
    Cell Death Differ; 2009 Mar 15; 16(3):498-511. PubMed ID: 19079141
    [Abstract] [Full Text] [Related]

  • 16. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
    Horinaka M, Yoshida T, Nakata S, Shiraishi T, Tomosugi M, Yoshikawa S, Wakada M, Sakai T.
    Cancer Sci; 2012 Feb 15; 103(2):282-7. PubMed ID: 22077238
    [Abstract] [Full Text] [Related]

  • 17. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY, Yue P, Hong WK, Lotan R.
    Cancer Res; 2000 Dec 15; 60(24):7149-55. PubMed ID: 11156424
    [Abstract] [Full Text] [Related]

  • 18. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
    Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C.
    Proc Natl Acad Sci U S A; 2006 Jul 25; 103(30):11160-5. PubMed ID: 16847267
    [Abstract] [Full Text] [Related]

  • 19. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, LoBuglio A, Kimberly R, Zhou T.
    Cancer Res; 2006 Sep 01; 66(17):8520-8. PubMed ID: 16951164
    [Abstract] [Full Text] [Related]

  • 20. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
    Tseng HY, Jiang CC, Croft A, Tay KH, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.
    Mol Cancer Ther; 2010 Dec 01; 9(12):3363-74. PubMed ID: 21159614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.